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Global and Local Conformation of human IgG Antibody Variants Rationalises Loss of 
Thermodynamic Stability 
In 2013, seven of the top ten selling drugs were therapeutic proteins, each grossing more 
than $5.5 billion annually.[1] Five of these medicines were monoclonal antibodies 
(Adalimumab, Infliximab, Rituximab, Bevacizumab and Trastuzumab) and another a fusion 
of an antibody Fc region to the ligand binding portion of human tumour necrosis factor 
(TNF) receptor (Etanercept). These drugs have been used to treat a number of different 
conditions including autoimmune disorders (Adalimumab, Etanercept and Infliximab) and 
cancers (Trastuzumab and Bevacizumab). There has been much recent interest in the 
treatment of cancer using novel antibody-based approaches, such as effector-enhanced, 
polyspecific and toxin-carrying antibodies. Molecular engineering efforts to modulate 
antibody properties, such as immune system recruitment, serum half-life extension and 
cytotoxic payload attachment are typically focused in the Fc region of IgG antibodies. This 
versatility demonstrates why the Fc region is a vital component of many protein drug 
molecules in clinical development. 
In contrast to small-molecule drugs, protein therapeutics are much larger and consequently 
have significantly more dynamic freedom.[2] Only a subset of these conformations will 
possess the desired activities (e.g. target binding) and some will be unstable.[3] These 
conformational dynamics are intrinsically related to thermodynamic stability and are 
implicated in the colloidal stability of the protein: for instance, structures may be populated 
that expose aggregation-prone motifs.[4] These fluctuations may not be appreciably 
reversible, and can lead to a degradation of the protein drug. 
Central to the drive to better understand the relationship between molecular structure, 
dynamics and stability is the development of analytical techniques that are spatially and 
conformationally resolved. Large and flexible molecules, such as monoclonal antibodies, are 
often difficult to study using high-resolution techniques, such as X-ray crystallography[5] and 
NMR.[6] Mass spectrometry (MS) is a core technology in the study of protein therapeutics 
due to its high selectivity, specificity and sensitivity.[7] Higher order structural information 
can be obtained by utilising emerging structural mass spectrometry techniques, including 
ion mobility coupled to mass spectrometry (IM-MS) and hydrogen/deuterium-exchange 
mass spectrometry (HDX-MS). 
It is becoming increasingly common to use IM-MS to obtain information regarding molecular 
(global) conformation since the technique can provide further information on the 
conformational ensemble that a protein can adopt.[8] IM-MS is also amenable to intrinsically 
disordered proteins, and has previously been used to investigate the differences in the 
conformational dynamics of intact, and Fc-fragments, for IgG1 and IgG4.[7e] 
HDX-MS has become established as a powerful technique for investigating the sub-
molecular (local) structure and dynamics of proteins.[9] By incubating a protein in a solution 
containing deuterium oxide (D2O), the resulting hydrogen/deuterium-exchange can be 
measured as an increase in mass (+1.006 Da per D). Each labile hydrogen atom in a 
polypeptide can exchange with those in solvent with a unique, observable rate constant 
(kex), related to the structure and dynamics of the protein’s local environment.[10] 
In this study, IM-MS and HDX-MS approaches have been utilised that, in combination, yield 
information on the global and local conformational dynamics of the antibody Fc region. 
Functional IgG1 mutants which have been engineered for reduced immune system 
recruitment and increased serum half-life have been studied, and the thermodynamic 
destabilisation exhibited when the mutations are combined has been examined.  
We compared the molecular (global) and sub-molecular (local) conformational dynamics of 
four human IgG1 Fc variants: a variant containing a triple mutation (TM) in the CH2 domain 
(L234F/L235E/P331S) that results in a decrease in affinity for Fc γ-receptor type IIIA 
(FcγRIIIA) and abrogates antibody dependent cellular cytotoxicity (ADCC)[11]; a YTE variant, 
containing a triple mutation in the CH2 domain (M252Y/S254T/T256E) that results in an 
increase in neonatal Fc receptor (FcRn) affinity at endosomal pH (~6.6) leading to a 4-fold 
increase in serum half-life in humans[12]; a TM/YTE variant, which contains both TM and YTE 
mutations; and a wild type (WT) IgG1 antibody, which contains neither TM or YTE 
mutations. 
We investigated the possibility that the introduction of these mutations could lead to a loss 
of thermodynamic stability. The thermal unfolding transitions for the CH2 domain from 44 
IgG1 antibodies were obtained using differential scanning calorimetry (DSC). The midpoint 
of the first unfolding transition (Tm1) was taken as a measure of the equilibrium 
thermodynamic stability of the CH2 domain[13]( 
Figure Legends 
Figure 1). Wild type human CH2 domains were found to be more stable (mean Tm1 70.1±0.7 
˚C). Thermal stability was found to be reduced in both TM (mean Tm1 64.1±0.4 ˚C) and YTE 
(mean Tm1 62.2±1.2 ˚C) variants. The inclusion of all six mutations led to a further decrease 
in the observed thermal stability of the CH2 domain (mean Tm1 58.1±1.4 ˚C). This combined 
effect may indicate negative co-operativity, although a purely additive effect is within error 
(Figure S1 in Supporting Information). If there is thermodynamic cooperativity between the 
two sets of mutations, then it is possible that a common site or sites within the protein may 
be responsible for translating the mutations into a difference in stability (ΔΔGD-N).  This 
hypothesis formed the basis of the subsequent structural dynamics studies. 
The global conformational dynamics of the IgG1 variant Fc regions were studied: shape and 
dynamics of the Fc region provide information on whether the mutations impact global 
stability via gross changes in structure and/or conformational dynamics. X-ray crystal 
models for the Fc region of the WT [14], TM [11a]  and YTE [12a] variants reveal that the WT and 
YTE are highly similar, but that there are large CH2 domain translation and rotation 
differences in the TM structure (Figure S3 in Supporting Information).  
From native MS experiments, the observed charge state distribution was consistent 
between all four variants (Figure S4 in Supporting Information). In all instances 11-14+ 
charge states were observed at similar relative intensities, consistent with previous studies 
on native IgG1 fragments.[7e] Resolving the populations of conformations adopted by these 
charge-states, IMS-MS also suggests there is little global conformational difference between 
the mutants; the most native-like 11+ charge state shows no change in estimated CCS values 
and arrival time distribution (ATD) between mutant variants, consistent with the molecules 
adopting a similar conformational ensemble. This is summarised in Figure 2. Native MS 
analysis suggests that the Fc structure of these antibodies displays no significant 
conformational change as a result of mutation. 
Increasing the charge on a protein induces unfolding, which is illustrated in Figure 2 for the 
four Fc variants. Each follows a common unfolding transition, with similar CCS values 
estimated for each structure. The CCS estimates for each drift time were consistent 
between variants, however the ATD profiles show differences between variants, primarily 
for the 13+ and 14+ charge states. At these charge states there is a higher relative intensity 
for the more unfolded structures in the TM and YTE variants. This becomes more 
pronounced in the TM/YTE variant. This is consistent with a proportionally lower unfolding 
energy barrier being present for these molecules as they more readily adopt their gas-phase 
unfolded structures relative to the wild type. This observation is in agreement with the 
trend evident from DSC data. Native MS experiments indicate that the Fc regions of these 
antibodies do not show significant differences in their global conformational dynamics.  
To investigate whether the thermodynamic differences were related to local conformational 
dynamics for these engineered IgG variants, HDX-MS experiments were carried out on 
isolated Fc regions. Sub-molecular localisation was provided by analysis of individual 
peptides that result from proteolytic digestion of the intact protein after deuterium 
labelling. The coverage and redundancy of the peptide map defines the detection and 
resolution at which structure and conformational dynamics may be observed. The peptide 
maps for all four Fc variants resulted in a sequence coverage of 93.8% and a redundancy of 
5.4 (Figure S5 in Supporting Information). Each peptide in the map was monitored for 
deuterium incorporation following dilution into 95% D2O. 
Three mutations in the antibody sequence in either the upper or lower CH2 domain (TM and 
YTE variants, respectively) have an impact on structure and/or conformational dynamics 
throughout the entire Fc region (Error! Reference source not found.6). These effects are 
both local to the site of mutation and also long ranging, reaching the posterior surface of 
the CH3 domain – a distance of 65 Å from the first TM mutation. The mutations 
predominantly induce deprotection to HDX, which results from increased exposure to 
solvent (as in a less compact conformational ensemble) and/or a reduction in intramolecular 
hydrogen-bonding. This is consistent with the trend observed in the DSC experiments; 
suggesting that the lower thermodynamic stability has a significant component derived from 
the protein (as opposed to solvent) enthalpy and entropy.  
HDX-MS permits spatial resolution of the sites within the Fc that contribute to this effect. 
The experiments reveal that the interior CH2 surface has the largest net change in deuterium 
incorporation between the wild type and the TM/YTE variant. Four degenerate peptides 
were identified that span β1-α1 of the CH2 domain (Figure 3 – HDX of the IgG1 CH2 domain 
interior surface. (a) Four overlapping peptides span the region of largest magnitude change 
in HDX between WT and TM/YTE (red). (b) X-ray crystal structure of wild type Fc (3AVE) 
predicts that four of the amide nitrogen atoms (blue spheres) are involved in stable 
hydrogen bonds (sticks: acceptor amino acids), which would confer significant protection to 
HDX. Green: YTE mutations. (c) D-label exchanged over time for the overlapping peptides 
for the four variants (black squares: WT; red triangles: TM; blue circles: YTE; purple 
triangles: TM/YTE). Unobservable amino acids (prolines and N-termini) in grey. X denotes 
methionine in WT and TM and tyrosine in YTE and TM/YTE.). Each show that TM and YTE 
mutations result in increased rates of deuterium incorporation relative to wild type. This 
observation is increased when the mutations are present together (Tables S1-4 in 
Supporting Information). An F-test analysis indicated that, for the TM/YTE variant, a two-
state model did not adequately fit the hydrogen-exchange observed in this region (P < 
0.0002 for all peptides). Using a three-state model, backbone amide groups exchanging for 
deuterium at an intermediate rate were observed, with a concomitant decrease in the 
number of amides undergoing exchange at the slow rate i.e. Aslow ≈ TM/YTEAslow + TM/YTEAinter. In 
the wild type and with TM or YTE mutations alone a two-state model was adequate to 
describe the hydrogen-exchange data (P ≥ 0.93). This suggests that, cooperatively, the 
TM/YTE mutations may destabilise the hydrogen-bonding network and/or increase the rate 
of structural dynamics in this region of the protein (Figure 3 – HDX of the IgG1 CH2 domain 
interior surface. (a) Four overlapping peptides span the region of largest magnitude change 
in HDX between WT and TM/YTE (red). (b) X-ray crystal structure of wild type Fc (3AVE) 
predicts that four of the amide nitrogen atoms (blue spheres) are involved in stable 
hydrogen bonds (sticks: acceptor amino acids), which would confer significant protection to 
HDX. Green: YTE mutations. (c) D-label exchanged over time for the overlapping peptides 
for the four variants (black squares: WT; red triangles: TM; blue circles: YTE; purple 
triangles: TM/YTE). Unobservable amino acids (prolines and N-termini) in grey. X denotes 
methionine in WT and TM and tyrosine in YTE and TM/YTE.).  
In this study we have applied a combination of emerging structural mass spectrometry 
techniques to investigate global (native IM-MS) and local (HDX-MS) conformational 
dynamics in the dominant class of medicine today: therapeutic monoclonal antibodies. 
Together, these techniques have been used to rationalise the destabilising effect of 
mutations in the IgG1 Fc region that serve to abrogate recruitment of natural killer cells 
(TM) or to enhance in vivo serum half-life (YTE). No significant experimental changes to the 
global conformational ensemble was observed using the native IM-MS approach. There was 
however a suggestion that the gas phase energy barrier to unfolding may have been 
reduced in the dual TM/YTE mutant. HDX-MS experiments reveal significant changes in the 
Fc region of the antibody for all the mutants studied. A number of long range disruptions to 
protein conformation which were observed may have been interpreted as global 
conformational changes without the benefit of the IM-MS data. The largest changes in 
conformational dynamics were at the interior face of the CH2 domain (β1-α1), suggesting, 
upon further statistical analysis, that there was a cooperative effect on the local structure 
and dynamics at this location, brought about by combining structurally distant TM and YTE 
mutations. In combination, the biophysical tools have been able to show that the mutations 
locally destabilise the CH2 interior surface, without significantly disturbing the global 
conformation of the Fc region. Taken together, these findings may explain the clear 
thermodynamic trend among a large number of antibodies tested and highlight a focused 
region of the molecule for future stability engineering work. The data presented here 
illustrate the power of MS-based technologies for the study of molecular structure and 
dynamics, notably in the field of therapeutic protein engineering and development where 
other, more established, structural techniques have proven to be relatively uninformative 
when used to study molecules of this size and mobility. We anticipate that these techniques 
will be used to focus mutagenesis campaigns in efforts to increase thermodynamic stability 
in next generation antibody and Fc-fusion protein therapeutics. 
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Figure Legends 
Figure 1 – Thermal stability by DSC for WT, TM, YTE and TM/YTE IgG1 antibodies. Midpoints 
of the first unfolding transition, assigned to the CH2 domain, are shown. Bars denote mean 
±1 S.D. 
Figure 2 – Global conformational ensembles for the Fc regions (54.7 kDa) of four engineered 
IgG1 variants. Collision cross section (CCS) variation with increasing molecular charge 
(11+:14+) were calculated from IM-MS drift time chromatograms under identical source and 
travelling wave conditions (see Supporting Information for experimental detail). 
Figure 3 – HDX of the IgG1 CH2 domain interior surface. (a) Four overlapping peptides span 
the region of largest magnitude change in HDX between WT and TM/YTE (red). (b) X-ray 
crystal structure of wild type Fc (3AVE) predicts that four of the amide nitrogen atoms (blue 
spheres) are involved in stable hydrogen bonds (sticks: acceptor amino acids), which would 
confer significant protection to HDX. Green: YTE mutations. (c) D-label exchanged over time 
for the overlapping peptides for the four variants (black squares: WT; red triangles: TM; blue 
circles: YTE; purple triangles: TM/YTE). Unobservable amino acids (prolines and N-termini) in 
grey. X denotes methionine in WT and TM and tyrosine in YTE and TM/YTE. 
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